StockData
Kymera Therapeutics, Inc. logo

Kymera Therapeutics, Inc. (KYMR) stock

KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30241% above fair value
$121.52−4.33 (-3.44%)

Close on Nov 17, 2026Market cap $10.37BP/E –Yield –

Kymera Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Kymera Therapeutics's gross margin for the twelve months ending Sep 30, 2026 was 0.0%. For fiscal 2025 it was 0.0%, against 0.0% the year before.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 20250.0%+0.0
FY2024Dec 31, 20240.0%+0.0
FY2023Dec 31, 20230.0%+0.0
FY2022Dec 31, 20220.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 20260.0%+0.0
Q1 FY2026Mar 31, 20260.0%+0.0
Q4 FY2025Dec 31, 20250.0%+0.0
Q3 FY2025Sep 30, 20250.0%+0.0
Q2 FY2025Jun 30, 20250.0%+0.0
Q1 FY2025Mar 31, 20250.0%+0.0
Q4 FY2024Dec 31, 20240.0%–
Q3 FY2024Sep 30, 20240.0%–
Q2 FY2024Jun 30, 20240.0%–
Q1 FY2024Mar 31, 20240.0%–

More Kymera Therapeutics figures

See a number that looks wrong?